Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Human Genetics Munich, |
RCV000128836 | SCV001150234 | pathogenic | Polyglucosan body myopathy type 1 | 2019-06-07 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV000128836 | SCV002103072 | pathogenic | Polyglucosan body myopathy type 1 | 2021-02-08 | criteria provided, single submitter | clinical testing | PVS1, PS4_moderate, PM2 |
Labcorp Genetics |
RCV000128836 | SCV003443938 | pathogenic | Polyglucosan body myopathy type 1 | 2022-10-16 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 140625). This premature translational stop signal has been observed in individuals with clinical features of polyglucosan body myopathy with or without immunodeficiency (PMID: 23798481, 29260357, 31407473). This variant is present in population databases (rs727503764, gnomAD 0.004%). This sequence change creates a premature translational stop signal (p.Glu299Valfs*46) in the RBCK1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RBCK1 are known to be pathogenic (PMID: 2379848, 23104095, 23889995). |
OMIM | RCV000128836 | SCV000172492 | pathogenic | Polyglucosan body myopathy type 1 | 2013-12-01 | no assertion criteria provided | literature only |